Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study

Overview

Journal Clin Transl Gastroenterol

Specialty Gastroenterology

Date 2022 Jan 26

PMID 35080508

Authors

Hokyou Lee

Hye Won Lee

Seung Up Kim

Hyeon Chang Kim

Affiliations

Soon will be listed here.

Abstract

Introduction: The association between nonalcoholic fatty liver disease (NAFLD) and colorectal cancer (CRC) has been controversial. Using the new consensus-driven definition, we evaluated the association of metabolic dysfunction-associated fatty liver disease (MAFLD) with the risk of developing CRC.

Methods: From a nationwide health screening database, we included 8,933,017 participants (48.6% male) aged 40-64 years between 2009 and 2010. Participants were categorized by the presence of fatty liver disease (FLD)-NAFLD and MAFLD, separately-and by the combination of the 2 definitions: neither FLD, NAFLD only, MAFLD only, or both FLD. The primary outcome was the development of CRC.

Results: Among the participants, 2,517,330 (28.2%) had NAFLD, and 3,337,122 (37.4%) had MAFLD, whereas 2,465,151 (27.6%) met both NAFLD and MAFLD definitions. Over a median follow-up period of 10.1 years, 60,888 new CRC cases developed. NAFLD and MAFLD were each associated with a significantly higher risk of developing CRC. When the neither FLD group was the reference, multivariable-adjusted hazard ratios (95% confidence interval) for CRC were 1.16 (1.06-1.28) in the NAFLD only group, 1.18 (1.16-1.20) in the both FLD group, and 1.32 (1.28-1.35) in the MAFLD only group. The presence of advanced liver fibrosis further increased CRC risk in each FLD group.

Discussion: FLD was associated with a higher risk of CRC development. CRC risk was higher in the presence of MAFLD, especially when accompanied by liver fibrosis.

Citing Articles

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.

Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C Hepatol Int. 2025; .

PMID: 40016576 DOI: 10.1007/s12072-024-10774-3.

Risk Factors for Colorectal Adenoma and Cancer in Comprehensive Health Checkups: Usefulness of Gamma-Glutamyltransferase.

Yamanouchi Y, Osawa M, Senbonmatsu T, Shiko Y, Kawasaki Y, Muramatsu T J Pers Med. 2024; 14(11).

PMID: 39590574 PMC: 11595480. DOI: 10.3390/jpm14111082.

Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives.

Torre E, Di Matteo S, Martinotti C, Bruno G, Goglia U, Testino G Clinicoecon Outcomes Res. 2024; 16:773-784.

PMID: 39469584 PMC: 11514691. DOI: 10.2147/CEOR.S472446.

Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.

Suoh M, Esmaili S, Eslam M, George J Hepatol Int. 2024; 18(6):1740-1755.

PMID: 39412611 PMC: 11632019. DOI: 10.1007/s12072-024-10731-0.

Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies.

Zhao J, Zhou B, Lv Y, Teng Q, Wang X, Li X Front Oncol. 2024; 14:1368965.

PMID: 39045565 PMC: 11263091. DOI: 10.3389/fonc.2024.1368965.

References

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

Seo H, Oh I, Yoon S . A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev. 2013; 13(12):6163-8. DOI: 10.7314/apjcp.2012.13.12.6163. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Wong V, Hui A, Tsang S, Chan J, Tse A, Chan K . Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006; 4(9):1154-61. DOI: 10.1016/j.cgh.2006.06.011. View

Cho S, Lee H, Lee H, Baek J, Heo J, Joo H . Dyslipidemia Fact Sheets in Korea 2020: an Analysis of Nationwide Population-based Data. J Lipid Atheroscler. 2021; 10(2):202-209. PMC: 8159761. DOI: 10.12997/jla.2021.10.2.202. View

Wong V, Kanwal F . On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. Clin Gastroenterol Hepatol. 2021; 19(5):865-870. DOI: 10.1016/j.cgh.2021.01.017. View

Quan H, Li B, Couris C, Fushimi K, Graham P, Hider P . Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011; 173(6):676-82. DOI: 10.1093/aje/kwq433. View

Lee Y, Lim Y, Park H . Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol. 2011; 27(1):91-5. DOI: 10.1111/j.1440-1746.2011.06816.x. View

Lee H, Yano Y, Cho S, Park J, Park S, Lloyd-Jones D . Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults. Circulation. 2020; 141(22):1778-1786. DOI: 10.1161/CIRCULATIONAHA.119.044838. View

10.

Lee J, Park Y, Yun J, Ahn Y, Lee K, Kim D . The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study. PLoS One. 2020; 15(1):e0226351. PMC: 6980645. DOI: 10.1371/journal.pone.0226351. View

11.

Basyigit S, Uzman M, Kefeli A, Sapmaz F, Yeniova A, Nazligul Y . Absence of non-alcoholic fatty liver disease in the presence of insulin resistance is a strong predictor for colorectal carcinoma. Int J Clin Exp Med. 2016; 8(10):18601-10. PMC: 4694373. View

12.

Kim H, Cho S, Lee H, Lee H, Baek J, Heo J . Korea hypertension fact sheet 2020: analysis of nationwide population-based data. Clin Hypertens. 2021; 27(1):8. PMC: 7958489. DOI: 10.1186/s40885-021-00166-2. View

13.

Cotter T, Rinella M . Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020; 158(7):1851-1864. DOI: 10.1053/j.gastro.2020.01.052. View

14.

Lin X, Shi K, You J, Liu W, Luo Y, Wu F . Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Mol Biol Rep. 2014; 41(5):2989-97. DOI: 10.1007/s11033-014-3157-y. View

15.

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

16.

Hong S, Choi W, Hwang H, Kim D, Yoon J, Wook Lee J . Chronic Viral Hepatitis Is Associated with Colorectal Neoplasia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021; 66(11):3715-3724. DOI: 10.1007/s10620-020-06745-x. View

17.

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

18.

Seong S, Kim Y, Park S, Khang Y, Kim H, Park J . Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. BMJ Open. 2017; 7(9):e016640. PMC: 5623538. DOI: 10.1136/bmjopen-2017-016640. View

19.

Ze E, Kim B, Jun D, Kim J, Kang H, Lee D . The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. Dis Colon Rectum. 2017; 61(1):36-42. PMC: 5728585. DOI: 10.1097/DCR.0000000000000973. View

20.

Adams L, Anstee Q, Tilg H, Targher G . Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017; 66(6):1138-1153. DOI: 10.1136/gutjnl-2017-313884. View